Online inquiry

IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15721MR)

This product GTTS-WQ15721MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ15721MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12860MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA OPN-305
GTTS-WQ13956MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ9953MR IVTScrip™ mRNA-Anti-hly, KBSA301(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA KBSA301
GTTS-WQ13917MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ12915MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OTSA101-DTPA
GTTS-WQ4154MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ1360MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-874
GTTS-WQ5241MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CB 2679d
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW